Navigation Links
NanoBio Expands Drug Development Team for Its Anti-Infective Products
Date:9/25/2007

ANN ARBOR, Mich., Sept. 25 /PRNewswire/ -- NanoBio(R) Corporation, a biopharmaceutical company developing novel anti-infective topicals and mucosal vaccines to treat and prevent serious infections, today announced the addition of four new scientists to its drug development team.

Lyou-fu Ma, PharmD, Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, Ph.D. and Paula L. Robinson will guide NanoBio in developing and commercializing its novel topical anti-infectives and mucosal vaccines. NanoBio's lead products are topical anti-infective lotions to eradicate cold sores and nail fungus, while its mucosal vaccines are in various stages of preclinical and human testing.

Dr. Ma has assumed the position of senior vice president of development and regulatory affairs, while Dr. Ciotti is the new director of formulation research and development at NanoBio Corporation. Dr. Hagan will serve as the senior manager of supply chain and Ms. Robinson will assume the position of clinical project manager.

"Each of our new scientific team members has a rich and diverse background in the pharmaceutical industry that will ensure our company's success as we accelerate our drug development programs," said James R. Baker, Jr., NanoBio's founder and chief science officer. "Their experience in taking compounds from preclinical testing through development will be invaluable in testing and developing our current and future products."

NanoBio's clinical programs for herpes labialis (cold sores) and onychomycosis (nail fungus) treatment have already yielded promising results, with clinical trials having demonstrated unparalleled safety and tolerability, added Baker. The collective experience of Ma, Ciotti, Hagan and Robinson will further expand the company's rich pipeline of products, he said.

Dr. Ma has 17 years of experience in the pharmaceutical industry. Prior to joining NanoBio, she served as development team leader in the pain therapy area at Pfizer Global Research and Development. In this leadership role, she was responsible for setting the strategic and operational direction for numerous compounds in development. She also led early- and mid-stage drug development teams in the neurosciences, inflammation and cardiovascular therapeutic areas at Pfizer. Prior to joining Pfizer, Dr. Ma was a principal scientist at Janssen Research Technology Center and was responsible for formulation development, scale-up, manufacturing and early analytical testing of rapid-melt dosage forms.

Dr. Ciotti joined NanoBio from the research formulations division at Pfizer, where she developed the preclinical and clinical formulations for the dermatology therapeutic area. Prior to joining Pfizer, she was a principal scientist at the Topical Formulations & Drug Delivery Technology Resource Center at Johnson & Johnson in Skillman, NJ. Dr. Ciotti currently serves as adjunct assistant professor at the University of Michigan, College of Pharmacy, where she teaches topical and transdermal drug delivery. She has published extensively and has patents pending and granted in the areas of drug delivery systems and manufacturing methods for semi-solids and liquid-liquid dispersions.

Dr. Hagan has more than 11 years of pharmaceutical industry experience in various aspects of drug product development. Prior to joining NanoBio, he served as supply chain coordinator, pharmaceutical sciences team leader, project manager, and analytical group leader for leading pharmaceutical companies, including Pfizer, Pharmacia Corporation and Warner-Lambert/Parke- Davis. Dr. Hagan contributed to the development of initial commercial products and line extensions for brands such as Rezulin(R), Caduet(R), Celebrex(R), and Zyvox(R).

Ms. Robinson has more than 19 years of drug development experience spanning from the pre-IND stage of development through regulatory approval. While at Warner-Lambert/Parke-Davis and Pfizer, Robinson held various positions within clinical research and development, worldwide project management, and development operations.

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), methicillin resistant Staphylococcus aureus (MRSA) and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, MI.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WARF expands license agreement with Advanced Cell Technology
2. Verizon expands broadband service in Wisconsin
3. Bandwidth provider expands in Milwaukee
4. Wisconsins biodiesel network expands
5. Quad/Graphics expands reach in western states
6. University of South Florida expands GE Healthcare relationship
7. Metavante expands healthcare payments division
8. Fiserv expands services to health plan market
9. Bone Care expands patent protection of core drug offering
10. SBC and AT&T merger expands global reach for Wisconsin businesses
11. Expetec expands IT staff services in Wisconsin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... have just published their findings on what they believe could be a new ... summary of the new research. Click here to read it now. ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... While the ... such as the Cary 5000 and the 6000i models are higher end machines that ... the height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):